Charles River Laboratories International, Inc. logo

Charles River Laboratories International, Inc. (RV6)

Market Open
17 Aug, 20:00
XDUS XDUS
245. 80
+5.7
+2.374%
- Market Cap
- P/E Ratio
- Div Yield
0 Volume
- Eps
240.1
Previous Close
Add Transaction
Day Range
240.6 245.8
Year Range
124.05 247.4
Want to track RV6 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

RV6 trading today higher at €245.8, an increase of 2.374% from yesterday's close, completing a monthly increase of 24.5503% or €48.45. Over the past 12 months, RV6 stock gained 45.4868%.
RV6 is not paying dividends to its shareholders.
The last earnings report, released on May 06, 2026, missed the consensus estimates by -2.05%. On average, the company has fell short of earnings expectations by -1.4633%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on NYSE (USD).

RV6 Chart

International Markets and Charles River (CRL): A Deep Dive for Investors

International Markets and Charles River (CRL): A Deep Dive for Investors

Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Zacks | 1 week ago
Charles River Laboratories International Q2 Earnings Call Highlights

Charles River Laboratories International Q2 Earnings Call Highlights

Charles River Laboratories International NYSE: CRL reported second-quarter results that exceeded its prior outlook, citing improved demand in its Discovery and Safety Assessment, or DSA, business and stronger-than-expected manufacturing performance. The company raised its full-year revenue, earnings and free-cash-flow guidance while maintaining a cautious view that the recovery in biopharmaceutical demand will progress gradually.

Marketbeat | 1 week ago
CRL Q2 Earnings and Revenues Top, '26 View Up, Stock Up in Pre-Market

CRL Q2 Earnings and Revenues Top, '26 View Up, Stock Up in Pre-Market

Charles River beats Q2 earnings and revenue estimates, raises 2026 outlook and gains 7.9% in pre-market trading.

Zacks | 1 week ago

Charles River Laboratories International, Inc. (RV6) FAQ

What is the stock price today?

The current price is €245.80.

On which exchange is it traded?

Charles River Laboratories International, Inc. is listed on XDUS.

What is its stock symbol?

The ticker symbol is RV6.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Charles River Laboratories International, Inc. ever had a stock split?

No, there has never been a stock split.

Charles River Laboratories International, Inc. Profile

Professional Services Industry
Industrials Sector
Birgit Girshick CEO
XDUS Exchange
US1598641074 ISIN
US Country
19,000 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Charles River Laboratories International, Inc. stands as a pivotal organization within the pharmaceutical industry, providing a comprehensive suite of services encompassing drug discovery, non-clinical development, and safety testing. With a global footprint that extends across the United States, Europe, Canada, the Asia Pacific, and other international markets, the company is recognized for its integrated solutions that support the entire drug development cycle. It operates through three primary segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing), each tailored to meet the varied and complex needs of its clients. Founded in 1947 and headquartered in Wilmington, Massachusetts, Charles River Laboratories is dedicated to aiding its clients in the development of novel therapies and medicines through its vast expertise and comprehensive facilities.

Products and Services

Research Models and Services (RMS): This segment is integral to Charles River Laboratories' operations, producing and selling a wide variety of research rodents, including purpose-bred rats and mice. These are essential tools for researchers across the globe, enabling a myriad of scientific investigations and discoveries. Services offered within this segment also include:

  • Genetically Engineered Models and Services: Customization and production of genetically modified animals to meet specific research requirements.
  • Insourcing Solutions: Provision of skilled personnel and resources to manage and operate clients' laboratory animal facilities.
  • Research Animal Diagnostic Services: Comprehensive diagnostic services to ensure the health and genetic integrity of research models.

Discovery and Safety Assessment (DSA): A critical segment that supports early-stage drug discovery and safety assessment. The DSA segment delivers:

  • Early and in vivo Discovery Services: Identification and validation of novel targets, chemical compounds, and antibodies, alongside the delivery of preclinical drug and therapeutic candidates ready for safety assessment.
  • Safety Assessment Services: Extensive testing services including toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics to ensure candidate drugs are safe for clinical trials.

Manufacturing Solutions (Manufacturing): This segment provides critical support in the quality control and testing of pharmaceuticals and consumer products. It encompasses:

  • In vitro Methods for Quality Control: Testing services for both sterile and non-sterile pharmaceuticals and consumer products, including specialized testing of biologics outsourced by pharmaceutical and biotechnology companies.
  • Contract Vivarium Operation Services: Operational support for biopharmaceutical clients’ vivarium facilities, ensuring the maintenance of high-quality standards in animal care and research.

Contact Information

Address: 251 Ballardvale Street
Phone: 781 222 6000